Clinical trials: Cardiac Magnetic Resonance Imaging
Atherosclerosis
Aliskiren Effect on Aortic Plaque Progression
This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta.
- Trial name
- ALPINE (NCT01417104)
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Ohio State University
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Iron, one of the most common elements in nature and the most abundant transition metal in the body, is readily capable of accepting and donating electrons.
- Trial name
- NCT01736540
- Testing
- MRI scan
- Where
- 13 sites in Australia
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation
This study characterized the impact of respiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry, vagal tone and depressed mood in patients with major depressive disorder…
- Trial name
- tVNS-MDD (NCT04467164)
- Testing
- exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS), Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Magnetic Resonance Imaging (MRI), Cardiac Pacing
Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment
The purpose of this study is to test the safety and effectiveness of the Medtronic CapSureFix Novus Model 5076 lead when patients are implanted with the Medtronic Advisa MRI pacemaker and undergo an MRI scan.
- Trial name
- NCT01755143
- Testing
- Magnetic Resonance Imaging scan sequences of the head, neck, and chest, Pacemaker System
- Where
- 36 sites in Australia, Austria and 17 more
- Volunteers
- 266 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Cardiac Disease
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as…
- Trial name
- BENEFIT2 (NCT03719612)
- Testing
- DEFINITY®
- Where
- 15 sites in United States
- Volunteers
- 160 people
- Sponsor
- Lantheus Medical Imaging
ISCHEMIC CARDIOMYOPATHY
Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease
The investigator hopes to introduce a novel MRI contrast agent with SeeMore ™ that directly defines viable myocardium. Identifying viable myocardium non-invasively using cardiac MRI is still a moving target and a question we plan…
- Trial name
- NCT01989195
- Testing
- 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Heart Disease, Ischemic, Atherosclerosis, Coronary
Comprehensive Evaluation of Ischemic Heart Disease Using MRI
The purpose of the study is to assess the diagnostic performance of fully automated motion corrected (MC) first pass myocardial perfusion MRI, compared to the original non-corrected first pass myocardial perfusion images in a…
- Trial name
- NCT01234870
- Testing
- Gadolinium, Adenosine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Coronary Artery Disease, Type 1 Diabetes Mellitus
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Cardiovascular disease (CVD) remains the major cause of mortality and morbidity in both type 1 (T1D) and type 2 (T2D) diabetes patients; modifications of traditional CVD risk factors have had a limited impact.
- Trial name
- RABIT1D (NCT01019486)
- Testing
- Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Colorado, Denver
Myocardial Perfusion Imaging, Magnetic Resonance Imaging
Myocardial Perfusion MRI
The object of this study is to compare four different dosages of Gadavist 1.0 in cardiac Magnetic Resonance Tomography (MRT) imaging with the imaging results of a cardiac SPECT examination in terms of diagnostic quality.
- Trial name
- NCT01490294
- Testing
- Gadobutrol (Gadavist,Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Germany and 2 more
- Volunteers
- 232 people
- Sponsor
- Bayer
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Coronary Artery Disease, Asthma
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson…
- Conditions
- Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
- Trial name
- NCT00763035
- Testing
- Regadenoson, Dobutamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences